Latest news about NGL Fine Chem
NGL Fine Chem
2,581.70
-63.40(-2.40%)
Company Performance:
View Company Insights1D-2.40%
1M+16.58%
6M+96.25%
1Y+135.77%
5Y+38.14%
More news about NGL Fine Chem
10Feb 26
NGL Fine Chem Reports Exceptional Q3 Results with EBITDA Surging 337% YoY
NGL Fine Chem reported outstanding Q3 performance with consolidated net profit jumping from ₹13 million to ₹157 million year-on-year, representing over 1,100% growth. The company's EBITDA surged 337% to ₹223 million with margin expansion to 17.50%. Revenue grew 44% to ₹1.28 billion driven by higher volumes across product portfolio. The company released its investor presentation showing strong operational metrics and ongoing expansion plans with ₹210 crore investment.
05Jan 26
NGL Fine-Chem Limited Announces Resignation of Company Secretary and Compliance Officer
NGL Fine-Chem Limited announced the resignation of Company Secretary and Compliance Officer Mrs. Pallavi Pednekar, effective January 23, 2026. She submitted her resignation on January 5, 2026, to pursue career opportunities outside the organization. The company confirmed no other material reasons for the departure and is actively seeking a replacement while maintaining full regulatory compliance.
12Nov 25
NGL Fine-Chem Reports Q2 FY2026 Results: Revenue Surges, Profit Slightly Dips
NGL Fine Chem Limited's Q2 FY2026 results show mixed performance. Revenue increased by 28.34% to ₹1,200.00 crore, while net profit marginally decreased by 2.04% to ₹96.00 crore. EBITDA grew by 47.41% to ₹171.00 crore, but EBITDA margin contracted by 303 bps to 14.25%. The Board of Directors approved these results on November 12, 2025, for the quarter ending September 30, 2025.
07Aug 25
NGL Fine-Chem Invests Rs. 119.83 Crore in Plant Expansion During Q1
NGL Fine Chem, a leader in the animal health sector, has invested Rs. 119.83 crore in Q1 for the expansion of its S-18 plant. The CAPEX completion is now expected in Q4 due to executional delays. Despite industry challenges, the company reported 14.80% YoY revenue growth to Rs. 104.19 crore in Q1. EBITDA increased by 17.36% to Rs. 10.97 crore, with a margin improvement of 23 basis points. The company remains focused on diversification into regulated markets for better profitability.
07Aug 25
NGL Fine-Chem Reports Robust Q1FY26 Performance Amid Industry Headwinds
NGL Fine-Chem Limited, a leading animal health company, reported robust Q1FY26 results. Revenue increased 9.70% QoQ to ₹104.19 crores, driven by higher volumes. EBITDA surged 73.64% to ₹10.97 crores, with margins improving to 10.53%. PAT jumped to ₹9.24 crores. The company faced challenges including intensified competition, downward pressure on product realizations, and currency volatility. Strategic initiatives include diversification into regulated markets and progress on a ₹160 crore greenfield expansion at Tarapur, with completion expected in Q4FY26.
01Aug 25
NGL Fine-Chem Reports Strong Q1 FY2026 Results with 18.6% Revenue Growth
NGL Fine-Chem Limited announced strong Q1 FY2026 results. Consolidated revenue increased 18.6% to ₹1,063.57 crore. Profit before tax surged 1,379.9% to ₹1,183.95 crore, while profit after tax grew 1,055.1% to ₹924.06 crore. Consolidated EPS stood at ₹29.91. Standalone performance was also robust with revenue at ₹1,074.15 crore and PAT at ₹764.41 crore. The company continues to focus on pharmaceutical manufacturing, with results including its wholly-owned subsidiary, Macrotech Polychem Private Limited.
22May 25
NGL Fine-Chem Reports Sharp Decline in Q4 Profits, Announces Dividend
NGL Fine-Chem's Q4 consolidated net profit fell 95.62% to ₹5.40 crore from ₹123.20 crore year-over-year. Revenue decreased 4.77% to ₹950.00 crore. EBITDA dropped 60.18% to ₹63.00 crore, with margin compression to 6.63%. Despite weak quarterly results, the company declared a dividend of ₹1.75 per share. Annual performance for FY 2024 showed improvement with revenue up 24.40% and net profit doubling compared to FY 2023.
26Mar 25
NGL Fine Chem Achieves Milestone with Partial Expansion at Plant S-18
NGL Fine Chem Limited has partially completed the expansion of Plant S-18 and commenced pilot batch production on March 11, 2025. The company has obtained necessary approvals from the Maharashtra Pollution Control Board (MPCB) for the expanded facility. This milestone marks a significant step in the company's growth strategy, potentially enhancing its production capabilities in the fine chemicals sector. The expansion is expected to increase production capacity and improve operational efficiency.
26Feb 25
NGL Fine-Chem Settles Disclosure Violation Case with SEBI for ₹92.21 Lakh
NGL Fine-Chem Limited and its promoters have settled with SEBI for ₹92.21 lakh regarding shareholding disclosure violations from 2002 to 2019. The company incorrectly classified PCI Ferrmone Chemicals as 'public/non-promoter' instead of 'promoter group' for 31 quarters. Promoters failed to disclose PCI Ferrmone's shareholding in their SAST disclosures. The settlement, reached without admission of guilt, includes payments from the company (₹54.42 lakh), PCI Ferrmone, and two promoters (₹12.60 lakh each). NGL Fine-Chem states the settlement won't impact its financial or operational activities beyond the payment.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,780.10
(-0.47%)
6,596.50
(+0.30%)
4,339.90
(-0.65%)
1,398.70
(+1.71%)
1,084.60
(+0.74%)
1,267.50
(+0.33%)
2,249.80
(-0.50%)
2,353.00
(-0.70%)
1,463.60
(+1.61%)
1,427.20
(+2.36%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
